Poor response to hepatitis A vaccination in hematopoietic stem cell transplant recipients.
Elen Monteiro AdatiPaula Moreira da SilvaLaura Massami SumitaMarina de Oliveira RodriguesLilian P ZanettiAna Cláudia F Dos SantosMair P de SouzaVergilio R ColturatoClarisse Martins MachadoPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2020)
In areas with intermediate/high seroprevalence of HAV, serology should be recommended prior to referral to vaccination. The mechanisms of antibody interference and how to overcome T-cell function deficiency need to be better understood in transplant populations receiving HAV vaccine. Alternative schedules of HAV vaccination should be evaluated in prospective trials.